Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Jul-Aug;15(4):102189.
doi: 10.1016/j.dsx.2021.102189. Epub 2021 Jun 28.

"Vitamin D supplementation and COVID-19 treatment: A systematic review and meta-analysis"

Dimple Rawat  1 , Avishek Roy  2 , Souvik Maitra  3 , Vivek Shankar  4 , Puneet Khanna  5 , Dalim Kumar Baidya  6
Affiliations
Meta-Analysis

"Vitamin D supplementation and COVID-19 treatment: A systematic review and meta-analysis"

Dimple Rawat et al. Diabetes Metab Syndr. 2021 Jul-Aug.

Abstract

Background: Vitamin-D is an immune-modulator which might be linked to disease severity by SARS-CoV-2.

Methods: Meta-analysis of RCTs and quasi-experimental studies, evaluating the role of vitamin-D supplementation in COVID patients was done.

Results: Total 5 studies (3 RCTs and 2 Quasi-experimental) including n = 467 patients were included. Vitamin D didn't reduce mortality (RR 0.55, 95%CI 0.22 to 1.39, p = 0.21), ICU admission rates (RR 0.20, 95% CI 0.01-4.26, p = 0.3) and need for invasive ventilation (RR 0.24, 95% CI 0.01-7.89, p = 0.42).

Conclusion: No significant difference with vitamin-D supplementation on major health related outcomes in COVID-19. Well-designed RCTs are required addressing this topic.

Keywords: COVID pneumonia; COVID-19; SARS-CoV-2; Vitamin-D.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study flow diagram.
Fig. 2
Fig. 2
Risk of bias summary based on Cochrane Systematic Review Guidelines for each included study (green for low risk of bias, blank for unclear risk of bias and red for high risk of bias) included in this review.
Fig. 3
Fig. 3
(3a-3c): Risk of bias graph review authors judgements about each risk of bias item presented as percentages across various study designs.
Fig. 4
Fig. 4
(a–c): Forest plot random effect model for vitamin D supplementation for various outcomes.
See this image and copyright information in PMC

Comment in

References

    1. WHO Coronavirus (COVID-19) dashboard. https://covid19.who.int
    1. Selvarajan S., et al. Systematic review on vitamin D level in apparently healthy Indian population and analysis of its associated factors. Indian J. Endocrinol. Metab. 2017;21:765–775. - PMC - PubMed
    1. Liu F., et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127:104370. - PMC - PubMed
    1. Yang X., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 2020;8:475–481. - PMC - PubMed
    1. Bernheim A., et al. Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. Radiology. 2020;295:200463. - PMC - PubMed